Instem plc Trading Update and Notice of Interim Results (4887U)
July 30 2015 - 2:00AM
UK Regulatory
TIDMINS
RNS Number : 4887U
Instem plc
30 July 2015
Instem plc
("Instem" or "the Company")
Trading Update and Notice of Interim Results
Instem (AIM: INS.L), a leading provider of IT solutions to the
global early development healthcare market, provides its trading
update for the six month period to 30 June 2015. Instem will be
announcing its Interim Results on Tuesday 29 September 2015.
In line with management expectations, the encouraging market
dynamics for the pre-clinical and clinical industries which helped
to generate a record order book as we entered 2015, began to be
converted into positive financial results in the first six months
of the financial year and this performance has continued post the
period end. Therefore, trading for full-year to 31 December 2015 is
expected to be in line with market expectations.
Management will be hosting a presentation for analysts on the
day of the results at 9.30am at the offices of Walbrook PR, 4
Lombard Street, London, EC3V 9HD. Analysts wishing to attend the
presentation should register their interest by emailing
instem@walbrookpr.com or by telephoning 020 7933 8780.
Phil Reason, CEO of Instem plc, commented: "The first half
results of the current financial year reflect many of the
investments in people and products the Company made during the
previous year. We continue to see positive trends across our target
markets and Management remains confident it can continue to deliver
further growth over the remainder of the year."
For further information, please contact:
Instem plc Tel: +44 (0) 1785 825 600
Phil Reason, CEO www.instem.com
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser Tel: +44 (0) 20 7496 3000
& Broker)
Richard Lindley
Nick Owen
Walbrook PR Ltd Tel: +44 (0) 20 7933 8780 or
Paul Cornelius instem@walbrookpr.com
Helen Cresswell
Sam Allen
About Instem
Instem is a leading supplier of IT applications to the early
development healthcare market, delivering compelling solutions for
data collection, management and analysis across the R&D
continuum. Instem applications are in use by customers worldwide,
meeting the rapidly expanding needs of life science and healthcare
organizations for data-driven decision making leading to safer,
more effective products.
Instem's portfolio of software solutions increases client
productivity by automating study-related processes while offering
the unique ability to generate new knowledge through the extraction
and harmonization of actionable scientific information.
Instem supports over 400 clients through full service offices in
the United States, United Kingdom and China with an additional
location in India and a full service distributor based in
Japan.
To learn more about Instem solutions and its mission, please
visit www.instem.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTLLFLRDVIAFIE
Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Instem (LSE:INS)
Historical Stock Chart
From Jul 2023 to Jul 2024